4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid
C20H24Cl2N4O3S — CID 156849764
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid
4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid (PubChem CID 156849764) has the molecular formula C20H24Cl2N4O3S and a molecular weight of 471.41 g/mol. Its IUPAC name is 4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid.
Molecular Properties
| Compound Name | 4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid |
|---|---|
| PubChem CID | 156849764 |
| Molecular Formula | C20H24Cl2N4O3S |
| Molecular Weight | 471.41 g/mol |
| Exact Mass | 470.09 |
| IUPAC Name | 4-[4-(3,4-dichlorophenyl)-5-(2-methylpropyl)-1,3-thiazol-2-yl]-1-(methylcarbamoyl)piperazine-2-carboxylic acid |
| SMILES | CNC(=O)N1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)c(CC(C)C)s2)CC1C(=O)O |
| InChI | InChI=1S/C20H24Cl2N4O3S/c1-11(2)8-16-17(12-4-5-13(21)14(22)9-12)24-20(30-16)25-6-7-26(19(29)23-3)15(10-25)18(27)28/h4-5,9,11,15H,6-8,10H2,1-3H3,(H,23,29)(H,27,28) |
| InChIKey | HXBMMSZNVOPGML-UHFFFAOYSA-N |
| XLogP | 4.23 |
| TPSA | 85.77 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 471.41 |
| LogP ≤ 5 | 4.23 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156849764 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.